Iovance Biotherapeutics Investor Presentation — January 2019

Document content

Corporate Presentation

January 2019This presentation contains “forward -looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Compan y,” “we,” “us,” or “our”). We may, in some cases, use

terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “ma y,”“could,” “might,” “will,” “should” or other words that convey

uncertainty of future events or outcomes to identify these forward -looking statements. The forward -looking statements include, b ut are not limited to, risks and uncertainties relating to

the success, timing, projected enrollment, manufacturing capabilities, and cost of our ongoing clinical trials and anticipate d clinical trials for our current product candidates (including

both Company -sponsored and collaborator -sponsored trials in both the U.S. and Europe), such as statements regarding the timing o f initiation and completion of these trials; the timing

of and our ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or oth er action with respect to, our product candidates; the

strength of Company’s product pipeline; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s

manufacturing, license or development agreements; the acceptance by the market of the Company’s product candidates, if approv ed;and other factors, including general economic

conditions and regulatory developments, not within the Company’s control. This presentation also contains certain preliminary financial numbers and estimates for the most recently

completed financial period. These numbers are good faith estimates based on currently available information and do not presen t all necessary information for an understanding of our

financial condition as of the most recently completed financial period. Readers are cautioned not to place undue reliance on these estimates, which are unaudited and remain subject to

review and adjustment by our auditors. As we complete our quarter -end financial close process and finalize the results for our most recently completed financial period, we may be

required to make significant judgments in a number of areas. The preliminary financial information presented herein has been prepared by and is the responsibility of our management.

The factors discussed herein could cause actual results and developments to be materially different from those expressed in o r implied by such statements. Actual results may differ from

those set forth in this presentation due to the risks and uncertainties inherent in the Company’s business, including, withou t limitation: the FDA may not agree with the Company’s